Microbot Medical's Losses Widen Amidst Significant Capital Influx

TL;DR

**MBOT is burning cash but just raised a ton of capital, so they're funded for now, but profitability is still a distant dream.**

AI Summary

Microbot Medical Inc. (MBOT) reported a net loss of $3.577 million for the three months ended September 30, 2025, an increase from $3.215 million in the same period of 2024. For the nine months ended September 30, 2025, the net loss widened to $9.678 million from $8.051 million in the prior year. Operating loss for the nine-month period increased to $10.605 million from $8.195 million. The company's cash and cash equivalents significantly increased to $6.704 million as of September 30, 2025, from $3.114 million at December 31, 2024, primarily due to $83.733 million raised from the issuance of common stock and warrants. Marketable securities also saw a substantial rise to $73.454 million from $2.356 million. Research and development expenses decreased to $1.171 million for the three months ended September 30, 2025, from $2.060 million in 2024, but increased to $4.741 million for the nine-month period from $4.646 million. Sales, General and Administrative expenses rose to $2.690 million for the quarter and $5.864 million for the nine months, up from $1.240 million and $3.549 million respectively. The company continues to incur losses due to ongoing R&D and pre-commercialization activities, but management believes current funds of approximately $80.158 million are sufficient for over twelve months of operations.

Why It Matters

Microbot Medical's substantial increase in cash and marketable securities, driven by over $83 million in equity financing, provides a critical lifeline for its ongoing robotic endoluminal surgery device development. For investors, this capital infusion mitigates immediate liquidity concerns, allowing the company to continue its R&D without imminent dilution, though the widening net losses remain a concern. Employees benefit from increased job security and continued investment in their projects. Customers and the broader market could eventually see new minimally invasive surgical technologies, potentially disrupting the competitive landscape dominated by larger medical device firms. The company's ability to sustain operations and advance its technology is crucial for its long-term viability and competitive positioning.

Risk Assessment

Risk Level: high — The company has not generated revenues from operations and reported a net loss of $9.678 million for the nine months ended September 30, 2025. While they have a cash and marketable securities balance of approximately $80.158 million, their reliance on future equity issuances and grants, coupled with the geopolitical risks in Israel where R&D is based, indicates a high-risk profile.

Analyst Insight

Investors should monitor MBOT's progress on its robotic endoluminal surgery devices and clinical milestones, as the company remains pre-revenue. The significant capital raise provides a buffer, but sustained losses and geopolitical risks warrant caution. Consider this a speculative long-term play on medical device innovation, but be prepared for continued volatility and potential future dilution.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

-$9.678M

eps

-$0.25

gross Margin

N/A

cash Position

$6.704M

revenue Growth

N/A

Key Numbers

• $9.678M — Net Loss (For the nine months ended September 30, 2025, widened from $8.051M in 2024)
• $80.158M — Cash and Marketable Securities (As of September 30, 2025, excluding restricted cash, up from $5.470M at Dec 31, 2024)
• $83.733M — Proceeds from Issuance of Common Stock and Warrants (For the nine months ended September 30, 2025, significantly boosting cash)
• $10.605M — Operating Loss (For the nine months ended September 30, 2025, increased from $8.195M in 2024)
• 67,158,044 — Shares of Common Stock Outstanding (As of November 12, 2025, indicating significant dilution from 19,399,513 shares at Dec 31, 2024)
• $4.741M — Research and Development Expenses (For the nine months ended September 30, 2025, increased from $4.646M in 2024)
• $5.864M — Sales, General and Administrative Expenses (For the nine months ended September 30, 2025, increased from $3.549M in 2024)
• $0.25 — Basic and Diluted Net Loss Per Share (For the nine months ended September 30, 2025, improved from $0.53 in 2024 due to increased share count)

Key Players & Entities

• Microbot Medical Inc. (company) — Registrant in its charter, medical device company
• NASDAQ Capital Market (regulator) — Exchange where MBOT common stock trades
• Microbot Medical Ltd. (company) — Private medical device company, subsidiary of Microbot Medical Inc.
• Israel (person) — Location of research and development operations
• Hamas (person) — Hostile force from Gaza
• Israeli Innovation Authority (company) — Potential source of additional grants
• SEC (regulator) — U.S. Securities and Exchange Commission
• Assad regime (person) — Former regime in Syria
• Houthis (person) — Group involved in military operations in Yemen
• Iranian regime (person) — Regime involved in military operations

FAQ

Risk Factors

• Reliance on Israeli Subcontractors and Vendors [high — operational]: The ongoing Israel-Hamas war poses a risk that Israeli subcontractors, vendors, and suppliers may not be fully operational. This disruption could impact the company's ability to execute its research and development and pre-commercialization activities, which are critical for future revenue generation.
• Disruption to International Flights and Logistics [medium — operational]: Military operations in Israel have led to a slowdown in international flights. This could affect the company's supply chain, personnel travel, and the timely delivery of necessary components or equipment, potentially delaying product development and commercialization efforts.
• Decreasing International Regard and Boycotts [medium — market]: There is a risk of decreasing international regard for Israeli-based companies due to geopolitical events. This, coupled with possible boycotts, could adversely affect Microbot Medical's ability to conduct business in certain jurisdictions or with specific industry groups and potential customers.
• Need for Future Capital Infusions [high — financial]: The company has not generated revenues and expects to continue incurring losses. Future operations are dependent on raising additional capital through equity or debt issuances, or grants. The ability to secure this funding on favorable terms is uncertain and subject to market demand and business risks.
• Significant Dilution from Stock Issuances [high — financial]: The company has significantly increased its outstanding shares of common stock from 19,399,513 at December 31, 2024, to 67,158,044 as of November 12, 2025. This substantial dilution impacts existing shareholders and may affect future per-share metrics.
• Pre-Commercialization Stage and Ongoing Losses [high — operational]: Microbot Medical is in a pre-commercialization phase, leading to significant operating losses. For the nine months ended September 30, 2025, the net loss was $9.678 million and the operating loss was $10.605 million. Continued losses are expected, requiring substantial funding.

Industry Context

Microbot Medical operates in the highly competitive and capital-intensive medical device sector, specifically focusing on robotic surgical technologies. The industry is characterized by long development cycles, significant R&D investment, and stringent regulatory hurdles. Companies in this space often rely on substantial funding rounds to advance their technologies through clinical trials and FDA approval processes before achieving commercial viability.

Regulatory Implications

As a medical device company, Microbot Medical is subject to rigorous regulatory oversight from bodies like the FDA. The development and commercialization of its products require adherence to strict quality and safety standards. Any delays or failures in the regulatory approval process could significantly impact the company's timeline to market and financial performance.

What Investors Should Do

1. Monitor R&D progress and milestones: Given the company's pre-revenue status, tracking advancements in its robotic surgical technologies is crucial for assessing future potential.
2. Evaluate cash burn rate and future financing needs: With ongoing losses, investors should scrutinize the company's cash runway and its ability to secure necessary future funding without excessive dilution.
3. Assess geopolitical risks: The ongoing impact of the Israel-Hamas war on operations, supply chains, and international business relationships should be closely monitored.
4. Analyze share dilution: The significant increase in outstanding shares requires careful consideration of its impact on existing shareholder value and future earnings per share.

Key Dates

• 2023-10-07: Israel-Hamas War begins — This geopolitical event directly impacts the company's primary operational base in Israel, introducing risks related to subcontractors, logistics, and international perception.
• 2025-09-30: End of Q3 2025 — Reporting period for the 10-Q, showing a net loss of $3.577 million for the quarter and $9.678 million for the nine months, with a substantial increase in cash and marketable securities due to stock issuance.
• 2025-10-10: Cease-fire with Hamas — Indicates a potential de-escalation of conflict, though risks remain ongoing. The company continues to monitor the situation.
• 2025-11-12: Shares of Common Stock Outstanding reported — Shows a significant increase in shares outstanding to 67,158,044 from 19,399,513 at year-end 2024, highlighting substantial equity financing and dilution.

Glossary

Marketable Securities

Investments that are readily convertible to cash, such as money market mutual funds or publicly traded stocks and bonds. (Microbot Medical's significant holdings in marketable securities ($73.454 million) provide a substantial portion of its liquidity, alongside cash equivalents.)

At-the-Market offering (ATM)

A type of public offering where a company sells its shares directly into the open market over a period of time, typically through a broker. (The company may utilize an ATM offering to raise additional capital, which could lead to further share dilution.)

US GAAP

United States Generally Accepted Accounting Principles, the standard framework of guidelines for financial accounting used in the U.S. (The financial statements are prepared in accordance with US GAAP, ensuring a standardized and comparable reporting format.)

Fair Value Hierarchy

A three-level valuation hierarchy that prioritizes the inputs used in determining the fair value of financial instruments. (Used to classify the company's financial assets (like marketable securities) based on the reliability of the inputs used for valuation, with Microbot's marketable securities being Level 1 (quoted prices in active markets).)

Pre-commercialization activities

Activities undertaken by a company before it begins generating revenue from its products or services, typically involving research, development, and market preparation. (These activities are the primary drivers of Microbot Medical's current operating losses and cash burn.)

Year-Over-Year Comparison

Compared to the prior year, Microbot Medical has significantly increased its cash and marketable securities position to $80.158 million as of September 30, 2025, primarily due to substantial equity financing. However, this has come with a considerable increase in outstanding shares, leading to significant dilution. The company continues to operate at a loss, with both net and operating losses widening for the nine-month period ended September 30, 2025, despite a decrease in R&D expenses for the third quarter. SG&A expenses have notably increased, reflecting ongoing pre-commercialization efforts.

Key Financial Figures

• $1 — $ ( 100,622 ) $ 78,224 (*) Less than $1. (1) Net of issuance costs in the am

Filing Documents

• form10-q.htm (10-Q) — 857KB
• ex31-1.htm (EX-31.1) — 19KB
• ex31-2.htm (EX-31.2) — 19KB
• ex32-1.htm (EX-32.1) — 6KB
• ex32-2.htm (EX-32.2) — 6KB
• 0001493152-25-021929.txt ( ) — 4736KB
• mbot-20250930.xsd (EX-101.SCH) — 37KB
• mbot-20250930_cal.xml (EX-101.CAL) — 37KB
• mbot-20250930_def.xml (EX-101.DEF) — 136KB
• mbot-20250930_lab.xml (EX-101.LAB) — 328KB
• mbot-20250930_pre.xml (EX-101.PRE) — 237KB
• form10-q_htm.xml (XML) — 686KB

- Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2 - Management's Discussion and Analysis of Financial Condition and Results of Operations 17

- Quantitative and Qualitative Disclosures About Market Risk

Item 3 - Quantitative and Qualitative Disclosures About Market Risk 23

- Controls and Procedures

Item 4 - Controls and Procedures 24

- Other Information

Part II - Other Information 25

- Legal Proceedings

Item 1 - Legal Proceedings 25

- Risk Factors

Item 1A - Risk Factors 25

- Unregistered Sales of Equity Securities and Use of Proceeds

Item 2 - Unregistered Sales of Equity Securities and Use of Proceeds 25

- Defaults Upon Senior Securities

Item 3 - Defaults Upon Senior Securities 25

- Mine Safety Disclosures

Item 4 - Mine Safety Disclosures 25

- Other Information

Item 5 - Other Information 25

- Exhibits

Item 6 - Exhibits 25

Signatures

Signatures 26 i MICROBOT MEDICAL INC. Interim Condensed Consolidated Balance Sheets U.S. dollars in thousands (Except share and per share data) As of As of Notes September 30, 2025 December 31, 2024 Unaudited Audited ASSETS Current assets: Cash and cash equivalents $ 6,704 $ 3,114 Marketable securities 2 73,454 2,356 Restricted cash 54 49 Prepaid expenses and other current assets 573 300 Total current assets 80,785 5,819 Property and equipment, net 78 80 Operating right-of-use assets 6 897 132 Total assets $ 81,760 $ 6,031 LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities: Accounts payable $ 509 $ 165 Lease liabilities 6 297 70 Accrued liabilities 2,128 2,225 Total current liabilities 2,934 2,460 Non-current liabilities: Long-term lease liabilities 6 602 41 Total liabilities 3,536 2,501 Shareholders' equity: Common stock; $ 0.01 par value; 120,000,000 and 60,000,000 shares authorized as of September 30, 2025 and December 31, 2024, respectively; 65,833,556 and 19,399,513 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively. 659 195 Additional paid-in capital 178,187 94,279 Accumulated deficit ( 100,622 ) ( 90,944 ) Total shareholders' equity 78,224 3,530 Total liabilities and shareholders' equity $ 81,760 $ 6,031 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 1 MICROBOT MEDICAL INC. Interim Condensed Consolidated Statements of Comprehensive Loss U.S. dollars in thousands 2025 2024 2025 2024 For the Three Months Ended September 30, For the Nine Months Ended September 30, 2025 2024 2025 2024 Unaudited Unaudited Research and development, net $ ( 1,171 ) $ ( 2,060 ) $ ( 4,741 ) $ ( 4,646 ) Sales, General and administrative ( 2,690 ) ( 1,240 ) ( 5,864 ) ( 3,549 ) Operating loss ( 3,861 ) ( 3,300

Risk Factors

Risk Factors To date, the Company has not generated revenues from its operations. As of September 30, 2025, the Company had cash equivalents and marketable securities balance of approximately $ 80,158 , excluding restricted cash. Due to continuing research and development and pre-commercialization activities, the Company expects to continue to incur additional losses for the foreseeable future. Notwithstanding these conditions, the Company's management has concluded that the available funds as of the balance sheet date, are sufficient to fund the Company's operations for more than twelve months from the issuance date of these financial statements. The Company may raise additional funds through future issuances of either debt and/or equity securities, including pursuant to a possible At-the-Market offering, upon cash exercise of outstanding investment options, and additional grants from the Israeli Innovation Authority and other government institutions. The Company's ability to raise additional capital in the equity and debt markets is dependent on a number of factors, including, but not limited to, the market demand for the Company's stock, which itself is subject to a number of development and business risks and uncertainties, as well as the uncertainty that the Company would be able to raise such additional capital at a price or on terms that are favorable to the Company. Israel-Hamas War On October 7, 2023, the State of Israel, where our research and development and other operations are primarily based, suffered a surprise attack by hostile forces from Gaza, which led to Israeli military operation at first in Gaza and then in Lebanon. These military operations and related activities, such as the recent collapse of the Assad regime in Syria and Israel's subsequent military operations in Syria, and the escalation of military operations by and against the Houthis in Yemen and the Iranian regime, are on-going as of the issuance date of these financial stateme

financial statements should be read in conjunction with the Company's latest audited financial statements

financial statements should be read in conjunction with the Company's latest audited financial statements. Operating results for the three and nine-month period ended September 30, 2025, are not necessarily indicative of the results that may be expected for the year ending December 31, 2025. NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The significant accounting policies followed in the preparation of these unaudited interim condensed consolidated financial statements are identical to those applied in the preparation of the Company's latest annual audited financial statements, except if noted below. Basis of presentation : The financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America ("US GAAP"). Use of estimates : The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions pertaining to transactions and matters whose ultimate effect on the financial statements cannot precisely be determined at the time of financial statements preparation. Although these estimates are based on management's best judgment, actual results may differ from these estimates. Fair value of financial instruments : The carrying values of cash and cash equivalents, restricted cash, prepaid expenses and other current assets, accounts payable and accrued liabilities approximate their fair value due to the short-term maturity of these instruments. 6 A fair value hierarchy is used to rank the quality and reliability of the information used to determine fair values. Financial assets and liabilities carried at fair value will be classified and disclosed in one of the following three categories: Level 1 - Quoted prices (unadjusted) in active markets for identical assets and liabilities. Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as unadjusted quoted prices for similar assets and liabi

View Full Filing

View this 10-Q filing on SEC EDGAR